公开(公告)号：US09017671B2

公开(公告)日：2015-04-28

申请号：US13660114

申请日：2012-10-25

Applicant: Genentech, Inc.

Inventor： James Andya ,  Shiang C. Gwee ,  Jun Liu ,  Ye Shen

IPC: A61K39/395 ,  C07K16/28 ,  C07K16/32

CPC classification number: A61K47/22 ,  A61K39/39541 ,  A61K39/39558 ,  A61K39/39591 ,  A61K47/26 ,  A61K2039/505 ,  C07K16/2878 ,  C07K16/32 ,  C07K16/40 ,  C07K2317/24 ,  C07K2317/94

Abstract: The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).

Abstract translation: 本申请描述了抗体制剂，包括在组氨酸 - 乙酸盐缓冲液中配制的单克隆抗体，以及包含结合HER2结构域II（例如，Pertuzumab）的抗体的制剂，以及包含与DR5结合的抗体 例如，Apomab）。

公开(公告)号：US09662395B2

公开(公告)日：2017-05-30

申请号：US13624381

申请日：2012-09-21

Applicant: Genentech, Inc.

Inventor： Junyan Ji ,  Jun Liu ,  Yuchang John Wang

IPC: A61K47/26 ,  A61K47/10 ,  A61K39/395 ,  A61K9/20 ,  A61K39/00 ,  C07K16/24 ,  C07K16/42 ,  G01N1/00 ,  A61K38/00

CPC classification number: A61K39/39591 ,  A61K9/2018 ,  A61K38/00 ,  A61K39/00 ,  A61K39/395 ,  A61K47/10 ,  A61K47/12 ,  A61K47/26 ,  C07K16/244 ,  C07K16/42 ,  C07K16/4291 ,  C07K2317/94 ,  G01N1/00

Abstract: The invention relates to use of non-surfactant compounds including, for example, polyoxyethylene (POE) sorbitans and polyethylene glycols (PEGs), for stabilizing protein-containing formulations and for the prevention of aggregation of proteins in such formulations.

公开(公告)号：US09487589B2

公开(公告)日：2016-11-08

申请号：US14534085

申请日：2014-11-05

Applicant: Genentech, Inc.

Inventor： Barthelemy Demeule ,  Bruce Kabakoff ,  Jun Liu ,  Nicole Piros ,  Qing Zhu

IPC: A61K39/395 ,  C07K16/28 ,  C07K16/40

CPC classification number: C07K16/2863 ,  A61K39/39591 ,  C07K16/40 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/56 ,  C07K2317/76

Abstract: Provided herein are pharmaceutical formulations comprising a one-armed, anti-c-met antibody and uses of the same.

Abstract translation: 本文提供了包含单臂，抗c-met抗体及其用途的药物制剂。

公开(公告)号：US11648317B2

公开(公告)日：2023-05-16

申请号：US16383478

申请日：2019-04-12

Applicant: Genentech, Inc.

Inventor： Ankit R. Patel ,  Jun Liu

IPC: A61K39/395 ,  A61K47/68 ,  A61J1/10 ,  A61K47/22 ,  A61K47/26 ,  A61K47/34 ,  A61K47/10 ,  A61K47/02 ,  A61K47/54 ,  A61K38/08 ,  C07K16/28 ,  A61K47/14

CPC classification number: A61K47/6811 ,  A61J1/10 ,  A61K38/08 ,  A61K47/02 ,  A61K47/10 ,  A61K47/14 ,  A61K47/22 ,  A61K47/26 ,  A61K47/34 ,  A61K47/542 ,  A61K47/6873 ,  C07K16/2803 ,  C07K2317/24 ,  C07K2317/56

Abstract: The disclosure provides stable pharmaceutical compositions comprising an anti-CD79b immunoconjugate and a surfactant. The disclosure also provides methods for using such compositions for the treatment of cancer.

公开(公告)号：US10166293B2

公开(公告)日：2019-01-01

申请号：US14201346

申请日：2014-03-07

Applicant: Genentech, Inc. ,  Novartis AG

Inventor： Jun Liu ,  Steven J. Shire

IPC: A61K47/02 ,  A61K39/395 ,  C07K16/42 ,  A61K9/19 ,  A61K39/00

Abstract: The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations.

公开(公告)号：US20150064191A1

公开(公告)日：2015-03-05

申请号：US14534085

申请日：2014-11-05

Applicant: GENENTECH, INC.

Inventor： Barthelemy Demeule ,  Bruce Kabakoff ,  Jun Liu ,  Nicole Piros ,  Qing Zhu

IPC: C07K16/28 ,  C07K16/40

CPC classification number: C07K16/2863 ,  A61K39/39591 ,  C07K16/40 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/56 ,  C07K2317/76

Abstract: Provided herein are pharmaceutical formulations comprising a one-armed, anti-c-met antibody and uses of the same.

Abstract translation: 本文提供了包含单臂，抗c-met抗体及其用途的药物制剂。

公开(公告)号：US20130058958A1

公开(公告)日：2013-03-07

申请号：US13666990

申请日：2012-11-02

Applicant: Genentech, Inc.

Inventor： Mayumi N. Bowen ,  Jun Liu ,  Ankit R. Patel

IPC: A61K39/395

CPC classification number: A61K39/39591 ,  A61K47/18 ,  A61K47/183 ,  C07K16/2812

Abstract: The invention relates to use of certain compounds including, for example, certain charged amino acids and structural analogs thereof, for reducing the viscosity of aqueous protein-containing formulations. Associated compositions of matter and methods of use are also contemplated within the present invention.

Abstract translation: 本发明涉及某些化合物（例如某些带电荷的氨基酸及其结构类似物）用于降低含蛋白质含量制剂的粘度的用途。 在本发明中也考虑了物质和使用方法的相关组合物。

公开(公告)号：US10034940B2

公开(公告)日：2018-07-31

申请号：US14599301

申请日：2015-01-16

Applicant: GENENTECH, INC. ,  Novartis AG

Inventor： Jun Liu ,  Steven J. Shire

IPC: A61K39/395 ,  A61K9/00 ,  A61K47/18 ,  A61K47/26 ,  C07K16/42 ,  A61K45/06 ,  A61K47/22 ,  A61K9/08 ,  A61M5/20 ,  A61K39/00

CPC classification number: A61K39/39591 ,  A61K9/0019 ,  A61K9/08 ,  A61K39/39566 ,  A61K45/06 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26 ,  A61K2039/505 ,  A61M5/20 ,  C07K16/4291 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/94 ,  Y10S435/80

Abstract: The present application relates to highly concentrated antibody and protein formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration. The application further describes articles of manufacture containing such formulations and method for using them to treat disorders treatable by the formulated antibody or protein.

公开(公告)号：US20170137535A1

公开(公告)日：2017-05-18

申请号：US15336578

申请日：2016-10-27

Applicant: Genentech, Inc.

Inventor： Christopher Petry ,  Benson Gikanga ,  Hung-Wei Chih ,  Jun Liu

IPC: C07K16/40 ,  A61K9/00 ,  A61K47/26 ,  A61K47/22 ,  A61K39/395 ,  A61K47/18

CPC classification number: C07K16/40 ,  A61K9/0048 ,  A61K9/08 ,  A61K9/19 ,  A61K39/39591 ,  A61K47/183 ,  A61K47/26 ,  C07K16/18

Abstract: Pharmaceutical formulations comprising monoclonal anti-Factor D antibodies, and their production and use for the treatment of complement-associated ocular diseases are disclosed. The formulations include pre-lyophilized, lyophilized and reconstituted stable liquid formulations of anti-Factor D antibodies, including lampalizumab.